secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2024-07-24T23:59:59+00:00
Accession:  0001099800-24-000069
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q2 revenue +8% CC, TAVR guidance cut to 5-7%; announces $1.2B in acquisitions
--------------------------------------------------------------------------------

- Q2 continuing ops sales $1.35B (+7% reported, +8% CC); adj. EPS $0.70, GAAP EPS $0.61.
- TAVR sales $1.0B, growth 5% (6% CC); FY2024 TAVR guidance lowered to 5-7% from 8-10%.
- TMTT sales $83M, +75%; FY2024 TMTT guidance raised to high end of $320-340M range.
- Entered agreement to acquire JenaValve (aortic regurgitation) and exercised option to acquire Endotronix (PA pressure sensor); total upfront ~$1.2B cash plus up to $445M milestones.
- Critical Care sale ($4.2B) on track to close late Q3 2024; Q3 sales guidance $1.56-1.64B, EPS $0.67-0.71.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980024000069/0001099800-24-000069-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980024000069/ew-20240724.htm
  HTML page:      https://secwatch.observer/filing/0001099800-24-000069

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer